Literature DB >> 3849979

Modulation of the immunosuppressive effects of splenic macrophages in Fischer rats bearing adenocarcinoma 13762.

J Bonaventure, V N Nigam, C A Brailovsky.   

Abstract

The nature of spleen cells in Fischer rats bearing a large size (greater than 1 cm diameter) mammary adenocarcinoma 13762A (MAC) which block the immunostimulating capacities of MTP2 (a synthetic immunomodulator) and suppress proliferation in vitro of splenic T and B lymphocytes by their respective mitogens was investigated. Splenic macrophages were recognized as the suppressor cells by (a) restoration of mitogenic responses by depletion of macrophages from spleen cell suspensions and (b) continued suppressor activity in spleen cell suspensions of tumor bearers devoid of viable T lymphocytes. Macrophage contact with T lymphocytes was required for the inhibition of T lymphocyte proliferation by concanavalin A as shown by (a) the absence of suppressor activity in supernatants derived from cultured suppressor macrophages, (b) lowering of the suppressor activity of intact macrophages after treatment with neuraminidase, (c) lowering of the suppressor activity of macrophages by addition of red cells to spleen cultures of tumor bearers indicating red cell interference with macrophage-T cell interaction and (d) lack of inhibiting action of suppressor macrophages on allogenic T lymphocyte proliferation showing macrophage T cell recognition for suppression. Animals bearing a large size tumor exhibited spleen hypertrophy and an increase in macrophage: lymphocyte ratio and a decrease in red cell: lymphocyte ratio. Splenic macrophages did not appear to be implicated in blocking antitumor immunity induction since (a) suppressor macrophages were absent in spleens during the inductive phase of the immune response and (b) MAC implanted in allogenic Wistar rats grew to about 2 cm diameter, induced splenic suppressor macrophages but the tumor was later rejected by the animals. Collectively the results suggest that suppressor macrophages are the result of increasing tumor volume rather than its cause.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3849979     DOI: 10.1007/bf00205684

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  42 in total

1.  Suppression of proliferative response and lymphokine production during the progression of a spontaneous tumor.

Authors:  L Varesio; M Giovarelli; S Landolfo; G Forni
Journal:  Cancer Res       Date:  1979-12       Impact factor: 12.701

2.  Inhibition of 3H-thymidine incorporation of lymphocytes by a soluble factor from macrophages.

Authors:  H G Opitz; D Niethammer; H Lemke; H D Flad; R Huget
Journal:  Cell Immunol       Date:  1975-04       Impact factor: 4.868

3.  Esterases in human leukocytes.

Authors:  C Y Li; K W Lam; L T Yam
Journal:  J Histochem Cytochem       Date:  1973-01       Impact factor: 2.479

4.  Presence of suppressor cells in spleens of mice bearing a weakly immunogenic syngeneic tumor.

Authors:  S C Gautam; S D Deodhar
Journal:  Cancer Res       Date:  1979-08       Impact factor: 12.701

5.  Adjuvant immunotherapy of N-[4(5-nitro-2-furyl)-2-thiazolyl]-formamide-induced bladder tumors.

Authors:  E H Ibraheim; H El Kappany; V N Nigam; C A Brailovsky; P Madarnas; M M Elhilali
Journal:  Anticancer Res       Date:  1984 May-Jun       Impact factor: 2.480

6.  A comparative study of the intravesical MTP and BCG treatment of transplantable bladder cancer.

Authors:  M M Elhilali; E H Ibrahim; V N Nigam; C A Brailovsky; P Madarnas
Journal:  J Urol       Date:  1983-06       Impact factor: 7.450

7.  Maltose tetrapalmitate, a nontoxic immunopotentiator with antitumor activity.

Authors:  V N Nigam; C A Brailovsky; C Chopra
Journal:  Cancer Res       Date:  1978-10       Impact factor: 12.701

8.  Mechanisms of immunosuppression in tumor-bearing mice: a multifactorial analysis.

Authors:  J M Jessup; B D Kahan; N R Pellis
Journal:  Cancer       Date:  1982-03-15       Impact factor: 6.860

9.  The antitumour activity of maltose tetrapalmitate compared with other immunoadjuvants, and its effectiveness after tumour surgery.

Authors:  H El Kappany; C Chopra; V N Nigam; C A Brailovsky; M Elhilali
Journal:  Br J Cancer       Date:  1980-11       Impact factor: 7.640

10.  Effects of structural variations in synthetic glycolipids upon mitogenicity for spleen lymphocytes, adjuvancy for humoral immune response and on anti-tumour potential.

Authors:  V N Nigam; J Bonaventure; C Chopra; C A Brailovsky
Journal:  Br J Cancer       Date:  1982-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.